Meridian Wealth Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Meridian Wealth Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,000	Closed	-$154K	–	557
2022 Q4	$154K	Sell	15,000 -12,000	-44%	-$107K	0.02%	500
2022 Q3	$210K	Hold	27,000	–	–	0.02%	448
2022 Q2	$142K	Sell	27,000 -15,094	-36%	-$94.9K	0.01%	526
2022 Q1	$467K	Hold	42,094	–	–	0.05%	249
2021 Q4	$416K	Hold	42,094	–	–	0.04%	265
2021 Q3	$415K	Buy	42,094 +15,094	+56%	+$151K	0.05%	249
2021 Q2	$279K	Buy	27,000 +8,100	+43%	+$82.3K	0.04%	315
2021 Q1	$193K	Buy	+18,900	New	+$208K	0.03%	352

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meridian Wealth Management's MLTX Position: Q1 2023 in Review

Meridian Wealth Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2023, closing a stake of 15,000 shares — an estimated $154K sold.

Meridian Wealth Management first reported a position in MLTX in Q1 2021 and held it in 8 quarters. The position peaked at $467K in Q1 2022. 43 funds tracked by Wall St. Rank hold MLTX as of Q1 2023.

Meridian Wealth Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2023 after selling out during the quarter.
Meridian Wealth Management sold 15,000 MoonLake Immunotherapeutics shares in Q1 2023, an estimated $154K.
Meridian Wealth Management first reported a position in MoonLake Immunotherapeutics in Q1 2021 and held it in 8 quarters.
Meridian Wealth Management's MoonLake Immunotherapeutics position peaked at $467K in Q1 2022.
43 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2023.

Based on Meridian Wealth Management's 13F filing for Q1 2023, filed 15 May 2023.